Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients
Uzma Zaidi,1 Bushra Kaleem,2 Munira Borhany,1 Sidra Maqsood,2 Naveena Fatima,2 Gul Sufaida,3 Saqib Hussain Ansari,1 Tasneem Farzana,1 Tahir Sultan Shamsi1 1Department of Clinical Hematology, National Institute of Blood Diseases & Bone Marrow Transplantation, Karachi, Pakistan; 2Department of...
Main Authors: | Zaidi U, Kaleem B, Borhany M, Maqsood S, Fatima N, Sufaida G, Ansari SH, Farzana T, Shamsi TS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-02-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/early-and-sustained-deep-molecular-response-achieved-with-nilotinib-in-peer-reviewed-article-CMAR |
Similar Items
-
Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
by: Khaleed J Khaleel, et al.
Published: (2018-01-01) -
Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report
by: Meng Xiao, et al.
Published: (2017-12-01) -
Chronic myeloid leukemia: successful therapy with nilotinib in a young patient with high Sokal risk and in sub-optimal response with imatinib
by: Fausto Palmieri
Published: (2015-10-01) -
The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
by: Muhammad Darwin Prenggono, et al.
Published: (2021-11-01) -
Nilotinib-Induced Elephantine Psoriasis In a Patient With Chronic Myeloid Leukemia: A Rare Case Report and Literature Review
by: Seyedeh Fatemeh Sadatmadani, et al.
Published: (2022-01-01)